The money is developing treatments for diabetes, cancer and Alzheimer's disease. It could also mean a cure for a Ridgefield ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

Shirley MacFarland’s weekly community column featuring news and notes from Brecksville, Broadview Heights, North Royalton and ...

U.S. Sen. Richard Blumenthal and researchers raise the alarm on how a federal medical research funding cap could impact "life ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...

Scotiabank lowered the firm’s price target on Sarepta (SRPT) to $80 from $105 and keeps a Sector Perform rating on the shares. After speaking ...

Providing a diverse range of perspectives from bullish to bearish, 4 analysts have published ratings on Capricor Therapeutics ...

The interim data found one child in the Duchenne trial produced more than double the amount of the protein needed to maintain ...

Korean researchers have proposed a new treatment strategy that can increase the effectiveness of the genetic rare disease ...

A Portland nonprofit is rewriting the story for people with disabilities by offering jobs, mentorship, and scholarships, helping to create opportunities that foster independence and success.